GoodRx Holdings (GDRX) Non-Current Debt (2019 - 2026)

GoodRx Holdings has disclosed Non-Current Debt across 8 years of filings, most recently posting $482.4 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $482.4 million, down 0.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $482.4 million (down 0.7% YoY), and the FY2025 annual result was $483.3 million, down 0.71% from the prior year.
• Non-Current Debt came in at $482.4 million for Q1 2026 at GoodRx Holdings, roughly flat from $483.3 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $654.8 million in Q1 2022 to a low of $482.4 million in Q1 2026.
• The 5-year median for Non-Current Debt is $646.7 million (2024), against an average of $582.2 million.
• Across the five-year window, Non-Current Debt decreased 0.61% in 2022 and fell 24.89% in 2025, its largest moves.
• GoodRx Holdings' Non-Current Debt stood at $651.8 million in 2022, then retreated by 0.63% to $647.7 million in 2023, then retreated by 24.86% to $486.7 million in 2024, then slipped by 0.71% to $483.3 million in 2025, then fell by 0.17% to $482.4 million in 2026.
• The last three Non-Current Debt figures came in at $482.4 million (Q1 2026), $483.3 million (Q4 2025), and $484.1 million (Q3 2025), per Business Quant data.